• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Metsera Inc.

    11/13/25 4:58:11 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTSR alert in real time by email
    S-8 POS 1 d18815ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on November 13, 2025

    Registration No. 333-284680

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to

    Form S-8

    Registration Statement No. 333-284680

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    METSERA, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   92-0931552

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    3 World Trade Center

    175 Greenwich Street

    New York, New York 10007

    (Address of Principal Executive Offices) (Zip Code)

    Metsera, Inc. 2023 Equity Incentive Plan

    Metsera, Inc. 2025 Incentive Award Plan

    Metsera, Inc. 2025 Employee Stock Purchase Plan

    (Full title of the plans)

    Margaret M. Madden

    Vice President

    Metsera, Inc.

    66 Hudson Boulevard East

    New York, NY 10001

    (Name and address of agent for service)

    (212) 733-2323

    (telephone number, including area code, of agent for service)

    Copies to:

    David K. Lam

    Jacob A. Kling

    Steven R. Green

    Wachtell, Lipton, Rosen & Katz

    51 West 52nd Street

    New York, New York 10019

    (212) 403-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

     

    ☐

      

    Accelerated filer

     

    ☐

    Non-accelerated filer

     

    ☒

      

    Smaller reporting company

     

    ☒

        

    Emerging growth company

     

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment relates to the Registration Statement on Form S-8 (File No. 333-284680) (the “Registration Statement”) previously filed by Metsera, Inc., a Delaware corporation (the “Company”), with the U.S. Securities and Exchange Commission on February 4, 2025, registering 20,094,557 shares of the Company’s common stock, par value $0.00001 per share, issuable in connection with the Company’s 2023 Equity Incentive Plan, the Company’s 2025 Incentive Award Plan and the Company’s 2025 Employee Stock Purchase Plan, as applicable.

    This Post-Effective Amendment is being filed in connection with the closing on November 13, 2025 of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2025, as amended by that certain Amendment No. 1 to Agreement and Plan of Merger, dated as of November 7, 2025 (as amended, the “Merger Agreement”), by and among Pfizer Inc., a Delaware corporation (“Parent”), Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company. On November 13, 2025, pursuant to the Merger Agreement, Merger Sub was merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

    As a result of the Merger, the Company has terminated all offerings of the Company’s securities pursuant to the Registration Statement. In accordance with undertakings made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offerings, the Company hereby removes from registration all such securities of the Company registered pursuant to the Registration Statement that remain unsold and any plan interests that are unissued as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities and the effectiveness of the Registration Statement is hereby terminated.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on November 13, 2025. No other person is required to sign this Post-Effective Amendment to the Registration Statement in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

    METSERA, INC.

    By:

     

    /s/ Margaret M. Madden

      Name: Margaret M. Madden
     

    Title:  Vice President

    Get the next $MTSR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTSR

    DatePrice TargetRatingAnalyst
    9/30/2025$54.00Overweight → Equal Weight
    Wells Fargo
    9/9/2025$77.00Outperform
    Leerink Partners
    6/20/2025$65.00Overweight
    Wells Fargo
    2/25/2025$56.00Buy
    Guggenheim
    2/25/2025$38.00Buy
    BofA Securities
    2/25/2025Outperform
    Evercore ISI
    More analyst ratings

    $MTSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burow Kristina converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:15:35 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Berns Paul L bought $14,219,964 worth of shares (789,998 units at $18.00) and converted options into 7,523,682 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:04:05 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Partners Xii, Llc converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    2/3/25 7:01:33 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    SEC Filings

    View All

    SEC Form 15-12G filed by Metsera Inc.

    15-12G - Metsera, Inc. (0002040807) (Filer)

    11/24/25 8:36:08 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.

    SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)

    11/17/25 1:59:38 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Metsera Inc.

    SCHEDULE 13D/A - Metsera, Inc. (0002040807) (Subject)

    11/14/25 6:22:29 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $MTSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Metsera downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Metsera from Overweight to Equal Weight and set a new price target of $54.00

    9/30/25 8:33:25 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Metsera with a new price target

    Leerink Partners initiated coverage of Metsera with a rating of Outperform and set a new price target of $77.00

    9/9/25 7:59:28 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Metsera with a new price target

    Wells Fargo initiated coverage of Metsera with a rating of Overweight and set a new price target of $65.00

    6/20/25 7:54:18 AM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    See Remark 1 Fmr Llc disposed of 2,233,460 shares (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    11/17/25 1:51:07 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Arch Venture Partners Xii, Llc returned 26,816,808 shares to the company (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    11/14/25 6:34:16 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF LEGAL OFFICER Lang Matthew returned 12,500 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Metsera, Inc. (0002040807) (Issuer)

    11/13/25 9:20:03 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pfizer Completes Acquisition of Metsera

    Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape Complements and transforms Pfizer's Internal Medicine portfolio Positions Pfizer to lead in one of the most dynamic and high-growth therapeutic areas Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. "This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resou

    11/13/25 11:26:00 AM ET
    $MTSR
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

    Revised transaction values Metsera at up to $86.25 per shareMetsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with PfizerTransaction creates real, certain and immediate value for Metsera's stockholders and ensures Metsera's important drug candidates can emerge as key competitors available to all patientsNEW YORK, Nov. 7, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value

    11/7/25 9:32:00 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Issues Statement in Response to Litigation Ruling

    NEW YORK, Nov. 5, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer: "Metsera is gratified by the Delaware Court of Chancery's decision to deny Pfizer's request for a temporary restraining order to block Metsera's Board of Directors from acting in the best interests of shareholders. Separately, Pfizer has reiterated it will continue to spuriously litigate. As we have previously noted, Pfizer's litigation arguments are nonsense. Metsera's Board of Directors will continue to stand firm on behalf of shareholders and patients." Disclosure Notice This rel

    11/5/25 7:17:00 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTSR
    Financials

    Live finance-specific insights

    View All

    Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

    Revised transaction values Metsera at up to $86.25 per shareMetsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with PfizerTransaction creates real, certain and immediate value for Metsera's stockholders and ensures Metsera's important drug candidates can emerge as key competitors available to all patientsNEW YORK, Nov. 7, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value

    11/7/25 9:32:00 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    /C O R R E C T I O N -- Metsera, Inc./

    In the news release, Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior", issued 04-Nov-2025 by Metsera, Inc. over PR Newswire, we are advised by the company that the second paragraph, third sentence, should begin "Shortly thereafter,..." rather than "On the same day,...", and the third paragraph, first sentence, should read "...representing up to $24.00 per share in cash (up from $21.25)..." rather than "...representing up to $24.00 per share in cash (up from $22.50)..." as originally issued inadvertently. The complete, corrected release follows: Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Ame

    11/4/25 9:09:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

    Novo Nordisk Amended Proposal Values Metsera at up to $86.20 per Share, a Total of Approximately $10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $70.00 per Share, a Total of Approximately $8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that a revised proposal that Metsera received from Novo Nord

    11/4/25 9:09:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care